Key terms
About TCRX
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TCRX news
Apr 18
5:32am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)
Apr 17
6:03am ET
TScan Therapeutics 2.473M share Spot Secondary priced at $7.13
Apr 16
4:32pm ET
TScan Therapeutics Advances in Solid and Hematological Cancer Therapy
Apr 16
4:27pm ET
TScan Therapeutics announces $125M common stock offering
Apr 08
8:16am ET
TScan Therapeutics appoints Chrysta Louis M.D CMO
Mar 10
8:15pm ET
Positive Outlook for TScan Therapeutics with Promising Clinical Trials and Strong Financial Position
Mar 07
7:35am ET
Strong Buy Rating for TScan Therapeutics Amidst Promising Drug Developments and Financial Health
Mar 07
7:07am ET
Barclays Sticks to Their Buy Rating for TScan Therapeutics (TCRX)
Mar 07
7:03am ET
TScan Therapeutics price target raised to $9 from $7 at Barclays
Mar 07
6:25am ET
Buy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 Results
Mar 06
4:13pm ET
TScan Therapeutics files $300M mixed securities shelf
Mar 06
7:04am ET
TScan Therapeutics reports Q4 EPS (21c), consensus (29c)
Feb 27
9:15am ET
Buy Rating Affirmed for TScan Therapeutics Following Promising TCR-T Therapy Trial Outcomes
Feb 27
6:28am ET
Strong Buy Rating for TScan Therapeutics Backed by Positive Phase 1 Trial Data and Promising Treatment Efficacy
Feb 27
3:28am ET
TScan Therapeutics (TCRX) Receives a Buy from Barclays
Feb 26
7:28am ET
TScan Therapeutics presents Phase 1 clinical results on TSC-100, TSC-101
Feb 21
7:57am ET
Buy Rating for TScan Therapeutics Supported by Iovance’s FDA Approval and Promising TIL Therapy Benchmark
Feb 14
7:09am ET
TScan to host virtual KOL event to discuss Phase 1 heme malignancies study
Feb 06
7:07am ET
TScan Therapeutics appoints Pinchasik as VP, Clinical Development
No recent press releases are available for TCRX
TCRX Financials
Key terms
Ad Feedback
TCRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TCRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range